Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Granules India Limited ( (IN:GRANULES) ) is now available.
Granules India Limited announced that its subsidiary, Granules Pharmaceuticals, Inc., received an Establishment Inspection Report from the US FDA following a Pre-Approval Inspection for a first-to-file controlled substance ANDA. The inspection, conducted in June 2025, resulted in one observation that has since been resolved, indicating the company’s commitment to maintaining regulatory standards.
More about Granules India Limited
Granules India Limited operates in the pharmaceutical industry, focusing on the production of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. The company is known for its emphasis on quality and regulatory compliance, serving a global market.
Average Trading Volume: 77,944
Technical Sentiment Signal: Strong Buy
Current Market Cap: 139.1B INR
See more insights into GRANULES stock on TipRanks’ Stock Analysis page.